Hone Health's Chronic Care Moat

The key advantage is that Hone is selling an ongoing care loop, not a one time prescription. Testosterone therapy usually starts with lab work, then repeated dose changes, follow up consults, and safety checks like hematocrit monitoring, because the right dose is individualized and can drift over time. That makes the relationship sticky in the same way GLP-1 obesity treatment is sticky, where the standard of care increasingly treats the condition as long term and relapsing rather than something fixed after one shipment.

• Hone is built around work that simple ED telehealth does not have to do. Patients need blood draws, lab review, medication titration, and recurring physician follow ups. That operational layer is harder to copy than shipping sildenafil or tadalafil, where many buyers can switch on price alone.
  1 sacra 2 sacra 6 sacra
• The economic result is higher lifetime value. In the 2024 model, Hone was already doing more than $150 in average order value with stronger retention, while Ro and Hims were described as having about 50% yearly churn in more transactional categories anchored in generic ED drugs.
  1 sacra 6 sacra 7 sacra
• This is also why Hone can widen from TRT into weight loss, menopause, and longevity. Once a patient is already doing recurring labs and consults, adding metformin, GLP-1s, or other hormone related therapies fits into the same care cadence. Hims is now moving this direction too, adding labs, menopause support, and testosterone offerings in 2025 and 2026.
  2 sacra 7 sacra 8 hims

Going forward, the winners in consumer telehealth are likely to look less like discount online pharmacies and more like subscription clinics for chronic care. Hone has a head start because its core product already trains customers to come back for labs, dose changes, and long duration treatment, which creates a base to compound into adjacent hormone and metabolic categories.